Patents Assigned to BUCK INSTITUTE FOR RESEARCH ON AGING
-
Publication number: 20240122890Abstract: In various embodiments method and compositions are provided for inducing weight loss in a mammal. In certain embodiments the methods involve administering to a mammal an effective amount of a fatty acid ?-hydroxyester compounds and/or one or more esters of butanediol.Type: ApplicationFiled: January 24, 2022Publication date: April 18, 2024Applicant: Buck Institute for Research on AgingInventors: John C. Newman, Brianna J. Stubbs
-
Patent number: 11814680Abstract: The present invention provides a method of detecting senescent cells or diagnosing cellular senescence in a subject wherein the level of one or more selected miRNAs is quantified in a sample from said subject.Type: GrantFiled: June 26, 2018Date of Patent: November 14, 2023Assignees: BUCK INSTITUTE FOR RESEARCH ON AGING, UNIVERSITÄT FÜR BODENKULTUR WIENInventors: Johannes Grillari, Matthias Hackl, Judith Campisi, Abhijit Kale
-
Patent number: 11773051Abstract: In various embodiments a compound comprising the enantiomerically enriched S-isomer S-BHB-S-1,3-butanediol is provided along with methods of use thereof.Type: GrantFiled: July 19, 2018Date of Patent: October 3, 2023Assignees: Buck Institute for Research on Aging, The Regents of The University Of California, The J. David Gladstone InstitutesInventors: Eric Verdin, John C. Newman
-
Publication number: 20230092706Abstract: Provided herein are methods for the treatment and/or prophylaxis of a viral pathology in a subject using one or more exogenous ketone(s).Type: ApplicationFiled: April 13, 2021Publication date: March 23, 2023Applicant: Buck Institute for Research on AgingInventors: Brianna J. Stubbs, John C. Newman
-
Publication number: 20220265605Abstract: In various embodiments compounds that induce and/or promote autophagy are provided as wells as methods of use thereof (e.g., in the prophylaxis or treatment of chronic pathologies associated with aging). In one illustrative, but non-limiting embodiments the compound(s) comprise, inter alia, coumarin 106.Type: ApplicationFiled: February 5, 2020Publication date: August 25, 2022Applicant: Buck Institute for Research on AgingInventors: Gordon J. Lithgow, Julie K. Andersen, Shankar J. Chinta, Manish Chamoli
-
Publication number: 20220251564Abstract: A p16INK4a inhibitor, a composition that includes the p16INK4a inhibitor, or a pharmaceutical composition that includes the p16INK4a inhibitor, for use in the prevention and/or the treatment of Huntington's disease, wherein the p16INK4a inhibitor is a nucleic acid or a peptide, a small compound molecule or a marketed drug.Type: ApplicationFiled: April 17, 2020Publication date: August 11, 2022Applicants: SORBONNE UNIVERSITE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, ASSISTANCE PUBLIQUE HOPITAUX DE PARIS, BUCK INSTITUTE FOR RESEARCH ON AGINGInventors: Christian NERI, Francesca FARINA, Jessica VOISIN, Lisa ELLERBY
-
Publication number: 20220241316Abstract: Methods and compositions are provided herein that pertain to the discovery that the crystallin alpha B (CRYAB) gene and gene product provides an effective target for senolytic agents. In certain embodiments, methods of selectively killing one or more senescent cells in a subject in need thereof are provided wherein the method involves administering to the subject an effective amount of an agent that inhibits expression and/or aggregation of a CRYAB protein.Type: ApplicationFiled: April 17, 2020Publication date: August 4, 2022Applicant: Buck Institute for Research on AgingInventors: Chandani Limbad, Ryosuke Doi, Munemichi Ohe, Naoki Inoue
-
Patent number: 11351167Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.Type: GrantFiled: September 26, 2019Date of Patent: June 7, 2022Assignees: Buck Institute for Research on Aging, Mayo Foundation for Medical Education and Research, Unity Biotechnology, Inc.Inventors: Remi-Martin Laberge, Judith Campisi, Marco Demaria, Nathaniel David, James L. Kirkland, Tamar Tchkonia, Yi Zhu, Darren J. Baker, Jan M. A. van Deursen
-
Patent number: 11325904Abstract: In various embodiments, compositions and methods are provided for treatment and/or prevention of amyloidogenic diseases. In certain embodiments, the methods entail administering an effective amount of a tropinol ester to a subject in need thereof for prophylactic or therapeutic effect. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In certain embodiments, methods of reducing the risk, lessening the severity, or delaying the progression or onset of a disease characterized by beta-amyloid deposits in the brain of a mammal are also provided. In certain embodiments, methods of directly or indirectly inhibiting the C-terminal cleavage of APP resulting in the formation of APP-C31 peptide and APPneo (AP-P664) in a mammal are provided.Type: GrantFiled: August 1, 2012Date of Patent: May 10, 2022Assignee: BUCK INSTITUTE FOR RESEARCH ON AGINGInventors: Varghese John, Dale E. Bredesen
-
Publication number: 20220000873Abstract: In various embodiments methods for the treatment or prophylaxis of an age-related and/or pathology-associated increase in intestinal barrier permeability are provided. In certain embodiments the methods comprise administering to a mammal in need thereof an effective amount of one or more agent(s) that inhibit superoxide or hydrogen peroxide production from the outer ubiquinone-binding site of complex III of the mitochondrial electron transport chain (site IIIQo).Type: ApplicationFiled: December 9, 2019Publication date: January 6, 2022Applicant: Buck Institute for Research on AgingInventors: Mark A. Watson, Martin D. Brand, Pankaj Kapahi
-
Patent number: 11091444Abstract: In certain embodiments hydantoin compounds are provided herein that are effective to inhibit BACE activity against APP. Without being bound to a particular theory, it is believed the activity of the hydantoins identified herein appears to be associated with binding to BACE and/or to APP particularly when these moieties form a BACE/APP complex. Accordingly, it is believed the compounds described herein represent a new class of compounds designated herein as APP-Binding-BACE Inhibitors (ABBIs) and provide a new mechanism to modulate APP processing. The hydantoins described herein appear to show improved brain permeability and functional BACE inhibition.Type: GrantFiled: January 10, 2020Date of Patent: August 17, 2021Assignee: BUCK INSTITUTE FOR RESEARCH ON AGINGInventors: Varghese John, Dale E. Bredesen
-
Patent number: 11066448Abstract: In various embodiments constructs are provided for the delivery of an effector molecule into a cell. In certain embodiments the construct comprises a cell penetrating peptide (CPP) attached to an effector that is to be delivered into a cell, where the cell penetrating peptide comprises a Zika cell penetrating peptide (Zika CPP), and the effector is selected from the group consisting of a protein, a nucleic acid, an organic compound, a nanoparticle, a viral particle, and the like.Type: GrantFiled: May 7, 2019Date of Patent: July 20, 2021Assignee: Buck Institute for Research on AgingInventors: Barbara J. Bailus, Lisa M. Ellerby
-
Patent number: 10844071Abstract: In certain embodiments compounds corresponding in structure to the formula: are provided that are effective to lower p-tau and/or to prevent or reduce elevation of p-tau, particularly in response to stress (e.g., elevated cortisol levels). The compounds are useful in the treatment or prophylaxis of pathologies characterized by abnormal amyloid plaque and or tangle formation and/or deposition.Type: GrantFiled: February 21, 2020Date of Patent: November 24, 2020Assignee: BUCK INSTITUTE FOR RESEARCH ON AGINGInventors: Varghese John, Dale E. Bredesen
-
Patent number: 10835546Abstract: In certain embodiments APP-specific BACE inhibitors (ASBIs) are provided as well as uses thereof. In certain embodiments methods of preventing delaying the onset of a pre-Alzheimer's condition and/or cognitive dysfunction, and/or ameliorating one or more symptoms of a pre-Alzheimer's condition and/or cognitive dysfunction, or preventing or delaying the progression of a pre-Alzheimer's condition or cognitive dysfunction to Alzheimer's disease are provided where the method involves administering to a subject in need thereof an APP specific BACE inhibitor (ASBI) in an amount sufficient to prevent or delay the onset of a pre-Alzheimer's cognitive dysfunction, and/or to ameliorate one or more symptoms of a pre-Alzheimer's cognitive dysfunction, and/or to prevent or delay the progression of a pre-Alzheimer's cognitive dysfunction to Alzheimer's disease. In certain embodiments the ASBI is a flavonoid (e.g. galangin) or flavonoid progrug (e.g., galangin prodrug).Type: GrantFiled: June 6, 2019Date of Patent: November 17, 2020Assignee: BUCK INSTITUTE FOR RESEARCH ON AGINGInventors: Varghese John, Dale E. Bredesen
-
Patent number: 10766867Abstract: In certain embodiments hydantoin compounds are provided herein that are effective to inhibit BACE activity against APP. Without being bound to a particular theory, it is believed the activity of the hydantoins identified herein appears to be associated with binding to BACE and/or to APP particularly when these moieties form a BACE/APP complex. Accordingly, it is believed the compounds described herein represent a new class of compounds designated herein as APP-Binding-BACE Inhibitors (ABBIs) and provide a new mechanism to modulate APP processing. The hydantoins described herein appear to show improved brain permeability and functional BACE inhibition.Type: GrantFiled: December 6, 2017Date of Patent: September 8, 2020Assignee: BUCK INSTITUTE FOR RESEARCH ON AGINGInventors: Varghese John, Dale E. Bredesen
-
Patent number: 10655144Abstract: This disclosure provides non-human animal models for age-related disorders and age-sensitive traits, particularly those caused by senescence-inducing stimuli, wherein the models comprise transgenes selectively expressed by senescent cells. The disclosure further provides methods for identifying therapeutic agents effective for treating or preventing age-related disorders and age-sensitive traits using the animal models, therapeutic agents identified using such methods, pharmaceutical compositions comprising the identified therapeutic agents, and methods of treating or preventing age-related disorders and age-sensitive traits.Type: GrantFiled: January 12, 2018Date of Patent: May 19, 2020Assignee: Buck Institute for Research on AgingInventors: Marco Demaria, Francis Rodier, Remi-Martin Laberge, Judith Campisi
-
Patent number: 10618899Abstract: Various [1,2,3]triazolo[4,5-d]pyrimidines are provided that are effective to lower p-tau and/or to prevent or reduce elevation of p-tau, particularly in response to stress (e.g., elevated cortisol levels). The compounds are useful in the treatment or prophylaxis of pathologies characterized by abnormal amyloid plaque and or tangle formation and/or deposition.Type: GrantFiled: February 17, 2016Date of Patent: April 14, 2020Assignee: Buck Institute for Research on AgingInventors: Varghese John, Dale E. Bredesen
-
Patent number: 10517866Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.Type: GrantFiled: May 16, 2018Date of Patent: December 31, 2019Assignees: Unity Biotechnology, Inc., Buck Institute for Research on Aging, Mayo Foundation for Medical Education and ResearchInventors: Remi-Martin Laberge, James L. Kirkland, Tamar Tchkonia, Yi Zhu, Nathaniel David, Alain Philippe Vasserot, Darren J. Baker, Bennett G. Childs, Jan M. A. van Deursen
-
Patent number: 10517844Abstract: In various embodiments a cancer treatment method is provided based on inhibition of proline catabolism. When combined with p53 restoration therapy and/or inhibition of glutaminase, the inhibition of proline catabolism results in a “synthetic lethal” and synergistic anticancer response. Novel suicide inhibitors that induce the degradation of proline dehydrogenase (PRODH) are also provided. Also provided is a method of assaying PRODH to identify responders/non-responders to inhibition of proline catabolism and/or glutaminase.Type: GrantFiled: November 12, 2015Date of Patent: December 31, 2019Assignee: Buck Institute for Research on AgingInventors: Gary K. Scott, Christopher C. Benz
-
Patent number: RE49873Abstract: In certain embodiments APP-specific BACE inhibitors (ASBIs) are provided as well as uses thereof. In certain embodiments methods of preventing or delaying the onset of a pre-Alzheimer's condition and/or cognitive dysfunction, and/or ameliorating one or more symptoms of a pre-Alzheimer's condition and/or cognitive dysfunction, or preventing or delaying the progression of a pre-Alzheimer's condition or cognitive dysfunction to Alzheimer's disease are provided where the method involves administering to a subject in need thereof an APP specific BACE inhibitor (ASBI) in an amount sufficient to prevent or delay the onset of a pre-Alzheimer's cognitive dysfunction, and/or to ameliorate one or more symptoms of a pre-Alzheimer's cognitive dysfunction, and/or to prevent or delay the progression of a pre-Alzheimer's cognitive dysfunction to Alzheimer's disease. In certain embodiments the ASBI is a flavonoid (e.g. galangin) or flavonoid prodrug (e.g., galangin prodrug).Type: GrantFiled: July 22, 2021Date of Patent: March 19, 2024Assignee: BUCK INSTITUTE FOR RESEARCH ON AGINGInventors: Varghese John, Dale E. Bredesen